HNGE
$42.48-2.03 (-4.56%)
Hinge Health, Inc.
Recent News
ImmuPharma, Ilika, Coinsilium Group, IP Group, Team Internet Group - Small Cap Week in Review
ImmuPharma (AIM:IMM, FRA:25I) says it's on track to deliver a licensing deal for its lead asset P140 this year. The company has also fast-tracked Kapiglucagon, a next-gen diabetes treatment, backed by funding from Lanstead Capital. Ilika (AIM:IKA, OTCQX:ILIKF, FRA:I8A) has had its Goliath solid-state batteries tested under battlefield conditions — including live-fire testing. The results demonstrated the inherent safety advantages of Ilika’s solid-state battery technology compared to traditional lithium-ion alternatives Coinsilium (AQSE:COIN, OTCQB:CINGF, FRA:5CT) is betting on prediction markets as its big focus for 2026. The sector is already worth over $65 billion, and the company is investing in Prediction Labs, which sits in the data infrastructure layer of the market. IP Group (LSE:IPO) posted 13% growth in NAV per share for 2025. Highlights include a near 50x return from the Hinge Health IPO and a £130 million valuation tied to Pfizer's obesity drug pipeline. Team Internet Group (AIM:TIG, OTCQX:TIGXF, FRA:4CN) says its transition year is done, with 80% of EBITDA now coming from its more stable domains and comparison platforms. The company is also reviewing a potential sale of the DIS division, with any proceeds targeted at repaying debt and rewarding shareholders. Follow us and subscribe on YouTune, our social channels, and on proactiveinvestors.co.uk.
IP Group H2 Earnings Call Highlights
IP Group (LON:IPO) reported full-year 2025 results showing an improvement in net asset value (NAV) per share, supported by a major uplift tied to a long-dated royalty and milestone interest in obesity drug compounds now being developed by Pfizer, alongside continued portfolio realizations and share
IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation
IP Group PLC (LSE:IPO) CEO Greg Smith talked with Proactive's Stephen Gunnion about the company’s 2025 results, highlighting 13% growth in NAV per share and the strategic developments across its portfolio. The discussion focused on how IP Group’s exposure to Pfizer’s acquisition of Metsera could generate significant long-term royalty income for shareholders. Smith explained that the company licenses the fundamental intellectual property behind an anti-obesity programme to Pfizer following the pharmaceutical giant’s acquisition of Metsera. The exposure has already been recognised with a £130 million asset valuation, equivalent to around 14p per share. The conversation also covered several portfolio milestones during 2025. These included the successful IPO of Hinge Health on the New York Stock Exchange, which generated strong returns for IP Group, delivering approximately 50 times the company’s original investment after exiting its position. Another key development was the sale of Monolith to Nasdaq-listed CoreWeave, bringing additional proceeds and further payments expected in 2026. Smith also discussed funding activity across the portfolio, including Artios Pharma’s $100 million Series D financing and a £100 million raise by autonomous vehicle company Oxa, backed by investors including the National Wealth Fund and Nvidia’s venture arm. Alongside investments, IP Group has continued to return capital to shareholders through share buybacks, while targeting £250 million in exits by the end of 2027. For more insights from company leaders and market updates, visit the Proactive YouTube channel, give this video a like, subscribe, and enable notifications so you never miss future interviews. #IPGroup #IPGroupPLC #GregSmith #LSEIPO #Pfizer #BiotechInvesting #VentureCapital #UKTech #HingeHealth #Oxa #Artios #HealthcareInnovation #GrowthInvesting #StockMarketUK
Is It Time To Reassess Hinge Health (HNGE) After Recent Musculoskeletal Care Coverage?
If you are wondering whether Hinge Health at around US$45 is priced attractively or already baking in a lot of optimism, you are not alone. Over the last month the share price has moved by 16.1%, while the last 7 days show a 2.5% decline and the year-to-date return sits at a 1.2% decline, which can leave investors questioning whether the recent moves reflect shifting expectations or just short term noise. Recent news coverage has focused on Hinge Health's position in digital musculoskeletal...
Gabriel Mecklenburg’s Share Sale And Conversion Reshape Hinge Health Valuation Story
Executive Chairman and Co Founder Gabriel Mecklenburg has completed a multi million dollar sale of Hinge Health (NYSE:HNGE) shares. The transaction also involved converting Class B shares into Class A shares, changing the mix of the company’s share classes. The move alters aspects of Hinge Health’s ownership and voting structure at a time when the stock is trading at $45.0. For you as an investor, this kind of insider activity can be an important signal to consider alongside the recent...